Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand (vol 37, pg 267, 2019)

被引：1
|
作者：
Chongmelaxme, Bunchai [1 ]
Phisalprapa, Pochamana [2 ]
Manthaisong, Ratree [3 ,4 ]
Dilokthornsakul, Piyameth [1 ]
Chaiyakunapruk, Nathorn [1 ,4 ,5 ,6 ]
机构：
[1] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Ctr Pharmaceut Outcomes Res, Phitsanulok 65000, Thailand
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med, Bangkok, Thailand
[3] Mahasarakham Univ, Fac Pharm, Dept Clin Pharm, Clin Pharm Res Unit, Maha Sarakham, Thailand
[4] Monash Univ Malaysia, Sch Pharm, Selangor, Malaysia
[5] Univ Wisconsin, Sch Pharm, Wisconsin, MA USA
[6] Monash Univ Malaysia, Asian Ctr Evidence Synth Populat Implementat & Cl, Hlth & Well Being Cluster, Global Asia Century Platform GA21 21, Bandar Sunway, Selangor, Malaysia
来源：
PHARMACOECONOMICS | 2019年 / 37卷 / 02期
关键词：
D O I：
10.1007/s40273-018-0754-y
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [1] Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand
    Bunchai Chongmelaxme
    Pochamana Phisalprapa
    Ratree Manthaisong
    Piyameth Dilokthornsakul
    Nathorn Chaiyakunapruk
    [J]. PharmacoEconomics, 2019, 37 : 291 - 291
  • [2] Screening diabetic patients for non-alcoholic fatty liver disease: Is it cost-effective
    Maor, Yaakov
    Zelber-Sagi, Shira
    Leshno, Moshe
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E38 - E38
  • [3] Weight reduction for non-alcoholic fatty liver disease
    Peng, Lijun
    Wang, Jiyao
    Li, Feng
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (06):
  • [4] A pilot study of pioglitazone for the treatment of non-alcoholic fatty liver disease
    Al-Gharabally, Abeer
    O'Brien, Christopher B.
    Acosta, Rita C.
    [J]. HEPATITIS MONTHLY, 2007, 7 (03) : 131 - 137
  • [5] Diet in Non-Alcoholic Fatty Liver Disease (vol 43, pg 24, 2019)
    Miller, Jennifer B.
    Henry, Zachary
    [J]. PRACTICAL GASTROENTEROLOGY, 2019, 43 (11) : 54 - 54
  • [6] Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes (vol 13, pg 2957, 2019)
    Rajput, Rajesh
    Ahlawat, Parul
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 472 - 472
  • [7] Coronavirus disease 2019 and non-alcoholic fatty liver disease
    Francesco Bellanti
    Gianluigi Vendemiale
    [J]. World Journal of Hepatology, 2021, (09) : 969 - 978
  • [8] Coronavirus disease 2019 and non-alcoholic fatty liver disease
    Bellanti, Francesco
    Vendemiale, Gianluigi
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (09) : 969 - 978
  • [9] Treatment of non-alcoholic fatty liver disease
    Takei, Yoshiyuki
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 79 - 80
  • [10] Treatment of Non-Alcoholic Fatty Liver Disease
    Scherer, Antonia
    Dufour, Jean-Francois
    [J]. DIGESTIVE DISEASES, 2016, 34 : 27 - 31
12345